Inflammation in pulmonary arterial hypertension: Is it time to quell the fire?

European Respiratory Journal

Volumn 43, Issue 3, 2014, Pages 685-688

  Hassoun, Paul M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; INTERLEUKIN 6; LIPOXYGENASE;

BLOOD VESSEL WALL; HEAT; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG BLOOD VESSEL; LYMPHOCYTE; MACROPHAGE; MORTALITY; PAIN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SKIN REDNESS; SWELLING;

CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN-6; MALE;

EID: 84895530133     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00006014     Document Type: Review

References (35)

1. Rather LJ. Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of Celsus. Bull N Y Acad Med 1971; 47: 303-22.
2. Heidland A, Klassen A, Rutkowski P, et al. The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance? J Nephrol 2006; 19: Suppl. 10, S102-S109.
3. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85.
4. Fartoukh M, Emilie D, Le Gall C, et al. Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998; 114: 50S-51S.
5. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
6. Sakamaki F, Kyotani S, Nagaya N, et al. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-2725.
7. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157: 219-229.
8. Voelkel NF, Tuder RM, Wade K, et al. Inhibition of 5-lipoxygenase- activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest 1996; 97: 2491-2498.
9. Isern RA, Yaneva M, Weiner E, et al. Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku. Am J Med 1992; 93: 307-312.
10. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005; 60: 765-772.
11. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26: 1110-1118.
12. Tamby MC, Humbert M, Guilpain P, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006; 28: 799-807.
13. Le Pavec J, Humbert M, Mouthon L, et al. Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: 1285-1293.
14. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.
15. Voelkel NF, Gomez-Arroyo J, Abbate A, et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012; 40: 1555-1565.
16. Cracowski JL, Leuchte HH. The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol 2012; 110: 32S-38S.
17. El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012; 55: 218-228.
18. Huertas A, Tu L, Gambaryan N, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 40: 895-904.
19. Malhotra R, Paskin-Flerlage S, Zamanian RT, et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 2013; 3: 369-380.
20. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920-927.
21. Cracowski J-L, Chabot F, Labarère J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J 2014; 43: 915-917.
22. Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J 2012; 40: 530-532.
23. Graham BB, Chabon J, Kumar R, et al. Protective role of IL-6 in vascular remodeling in schistosoma pulmonary hypertension. Am J Respir Cell Mol Biol 2013; 49: 951-959.
24. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-244.
25. Heresi GA, Aytekin M, Hammel JP, et al. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J 2014; 43: 912-914.
26. Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: 311-321.
27. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261-272.
28. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus-and mixed connective tissue diseaseassociated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008; 58: 521-531.
29. Nicolls M, Badesch DB, Medsger TA. A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH). http://clinicaltrials.gov/show/NCT01086540 Date last updated: August 17, 2013. Date last accessed: January 6, 2014.
30. Humbert M. Impression, sunset. Circulation 2013; 127: 1098-1100.
31. Wagenvoort CA. The pathology of primary pulmonary hypertension. J Pathol 1970; 101: Pi.
32. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206.
33. Pogoriler JE, Rich S, Archer SL, et al. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology 2012; 61: 597-609.
34. Kesten S, Dainauskas J, McLaughlin V, et al. Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin. Chest 1999; 116: 566-569.
35. Kudelko KT, Nadeau K, Leung AN, et al. Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay. J Heart Lung Transplant 2010; 29: 1071-1075.